Alphatec (ATEC) Wells Fargo 20th Annual Healthcare Conference 2025 summary

Financial performance and outlook

• Achieved sustained revenue growth and expanded profitability, with Q2 results exceeding expectations.

• Cash usage in Q2 was at the high end of guidance; positive free cash flow is expected for the full year and 2025.

• Q3 is projected to generate $1–$5 million in free cash flow, with high single-digit millions expected in Q4.

• Annual revenue growth guidance is 21%, with $130 million in total revenue growth projected for 2023, 2024, and 2025.

• Profitability expansion is enabling self-funding of investments in sets and inventory by 2026.

Market strategy and sales force development

• Focused on compelling surgeons with unique clinical solutions, resulting in 21% new surgeon adds in Q2.

• Existing territories grew 29% in Q2, with ongoing recruitment to support demand in both established and greenfield areas.

• New sales reps typically ramp up over two years, surpassing prior performance by year three.

• Revenue per procedure is about 30% higher than industry average, supporting rep income and growth.

• Investments in sets and inventory are aligned with revenue growth, maintaining a $0.75 spend per $1 of growth.

Innovation and product development

• Preparing for a late Q4 launch of the Valence robot, integrated with the PTP procedure to address clinical hurdles in lateral spine surgery.

• The robot features a small footprint, ease of use, and a sub-$500,000 price point, targeting broader adoption in ASCs and community hospitals.

• Differentiation includes integration with procedures, freehand navigation, and a unified instrumentation set.

• EOS Insight, launched in July 2024, offers automated alignment planning and patient-specific solutions, with ongoing enhancements.

• PTP Corpectomy expands the PTP platform, driving adoption through training and support, with indirect benefits to overall lateral practice.